Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
598.00    -11.00 (-1.81%)
Bid:
598.00
Ask:
600.00
Spread: 2.00 (0.334%)
Market Cap: £521.00m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

4 Oct 2012 07:00

RNS Number : 8822N
Victrex PLC
04 October 2012
 



For Stock Exchange Release at 7.00 a.m. Thursday 4 October 2012

 

Victrex plc

 

Year End Trading Statement and Board Appointment

 

Trading update for the year ended 30 September 2012

We are pleased to report that the positive trend in Group sales volume has continued with second half volume 7% ahead of the same period last year at 1,527 tonnes (H2 2011: 1,426 tonnes). This reflects strong new business commercialisation in our Victrex Polymer Solutions business ('VPS'). Full year volume increased to a new record of 2,904 tonnes (2011: 2,860 tonnes).

 

Full year revenue in our Invibio® Biomaterial Solutions business ('Invibio') was £50.5m (2011: £49.7m). Sales into the spine market were broadly in line with the prior year reflecting destocking at a select number of customers over the summer in response to the continued uncertainty in the US medical device industry. Revenue from our developing markets outside of spine grew by 11%, predominantly in arthroscopy.

 

Investment in capacity for growth

As we work with our customers and end users to create new opportunities for growth, demonstrating our ability to fulfil increased demand is critical. We are therefore pleased to confirm that we have commenced construction of a third PEEK plant on our Hillhouse site in Lancashire. This will increase our annual capacity by 2,900 tonnes to in excess of 7,000 tonnes. The total capital cost, including all related utility systems and infrastructure, is expected to be £90m which will be funded out of operating cash flow. The new plant is expected to be operational in early 2015.

 

Board appointment and management change

Tim Cooper, Managing Director of VPS, has been appointed as an Executive Director of the plc Board. Under Tim's leadership, VPS has made significant progress and he has provided valuable support to the plc Board since joining the business.

 

There are no other details to disclose under paragraph 9.6.13 of the Listing Rules in relation to Tim Cooper.

 

Hichem M'Saad, Managing Director of Invibio, has resigned for personal reasons. David Hummel, Chief Executive, will lead the Invibio Management Team to drive growth and further develop strategy for our established and targeted markets.

 

Outlook

The initial sales volume order book for October is encouraging. Whilst we are cognisant of the uncertain economic environment, our confidence in the growth potential for our business through the development of new applications and markets remains strong.

 

 

Victrex will announce its results for the year ended 30 September 2012 on Tuesday 11 December 2012.

 

 

Victrex will host a conference call at 8.30am today for analysts. If you would like more details, please call Rosa Smith at MHPC on 0203 128 8560 or email on Rosa.Smith@mhpc.com 

 

 

Enquiries

 

Victrex plc

David Hummel, Chief Executive

Steve Barrow, Finance Director

 

01253 898067

 

MHP Communications

Nick Denton / Barnaby Fry / Ian Payne

 

0203 128 8100

 

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK polymer, a high performance, easy to process thermoplastic.

 

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. We work with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Our VPS business focuses on our transport, industrial and electronics markets and our Invibio business focuses on providing specialist solutions for medical device manufacturers.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGCCUUPPGQW
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.